HUNTINGTON DISEASE: CURRENT ADVANCES IN PATHOGENESIS AND RECENT THERAPEUTIC STRATEGIES
Abstract
Huntington's disease (HD) is an inherited autosomal, progressive neurodegenerative disorder associated with involuntary abnormal movements (chorea), cognitive impairments and psychiatric disturbances. HD is caused by an abnormal expansion of a CAG region located in exon 1 of the gene encoding the huntingtin protein (Htt) and is the causative factor in the pathogenesis of HD. However, recent evidences show that impaired mitochondrial function plays a key role in the pathogenic processes of the desease. The underlying mechanisms by which mutant Htt (mHtt) causes HD have not been fully elucidated, however mutant Htt can impair mitochondrial function by dysregulation of transcriptional processes, calcium dyshomeostasis, and defective mitochondrial bioenergetics. Mutant Htt induce intracellular Ca2+ in neurons affected by HD and increased intracellular Ca2+ excessively enter mitochondria and induce to open the mitochondrial permeability transition pores (mPTP), leading to decreased mitochondrial ATP, and neuronal death. Transcriptional processes regulated by peroxisome proliferator-activated receptor γ (PPARγ) coactivator-1α (PGC-1α), which are critical for mitochondrial biogenesis, have also been shown to be impaired in HD. This review article discusses current developments, in determining the role of mitochondrial morphological and functional abnormalities contributing to the pathogenesis of HD and also discusses the current other possible therapeutic interventions.
Keywords:
Huntington disease, neurodegenerative disorder, pathogenesis, mitochondria.DOI
https://doi.org/10.25004/IJPSDR.2011.030201References
1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeats that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993; 72: 971–983.
2. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED Richardson EP Jr. Neuropathological classification of Huntington’s disease. J Neuropathol Exp Neurol. 1985; 44: 559–577.
3. Folstein SE. Huntington’s disease. Johns Hopkins University Press 1990.
4. Bates GP. History of genetic disease: the molecular genetics of Huntington disease a history. Nat Rev Genet. 2005; 6: 766–773.
5. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006; 443: 787–795.
6. Montoya A, Price BH, Menear M, Lepage M. Brain imaging and cognitive dysfunctions in Huntington’s disease. J Psychiatry Neurosci. 2006; 31: 21–29.
7. Gusella JF, MacDonald ME, Ambrose CM, Duyao MP. Molecular genetics of Huntington’s disease. Arch Neurol. 1983; 50: 1157–1163.
8. Vonsattel JP, M. DiFiglia M. Huntington disease. J Neuropathol Exp Neurol. 1998; 57: 369–384.
9. Kremer B. Clinical neurology of Huntington's disease. In: Bates G, Harper P, Jones L eds. Huntington's Disease. Oxford University Press; Edition 3; 2002: 28-53.
10. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 1996; 87: 493–506.
11. Reddy PH, Williams M, Charles V, Garrett L, Pike-Buchanan L, Whetsell WO, Jr, Miller G, Tagle DA. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat Genet. 1998; 20: 198–202.
12. Jackson GR, Salecker I, Dong X, Yao X, Arnheim N, Faber PW, MacDonald ME, Zipursky SL. Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons. Neuron. 1998; 21: 633–642.
13. Schilling G, Becher MW, Sharp AH, Jinnah HA, Duan K, Kotzuk JA, Slunt HH, Ratovitski T, Cooper JK, Jenkins NA, Copeland NG, Price DL, Ross CA, Borchelt DR. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet. 1999; 8: 397–407.
14. Kim M, Lee HS, LaForet G, McIntyre C, Martin EJ, Chang P, Kim TW, Williams M, Reddy PH, Tagle D, Boyce FM, Won L, Heller A, Aronin N, DiFiglia M. Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition. J Neurosci. 1999; 19: 964–973
15. Hodgson JG, Agopyan N, Gutekunst CA, Leavitt BR, LePiane F, Singaraja R, Smith DJ, Bissada N, McCutcheon K, Nasir J, Jamot L, Li XJ, Stevens ME, Rosemond E, Roder JC, Phillips AG, Rubin EM, Hersch SM, Hayden MR. A YAC mouse model for Huntington’s disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron. 1999; 23: 181–192.
16. Levine MS, Klapstein GJ, Koppel A, Gruen E, Cepeda C, Vargas ME, Jokel ES, Carpenter EM, Zanjani H, Hurst RS, Efstratiadis A, Zeitlin S, Chesselet MF. Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington’s disease. J Neurosci Res. 1999; 58: 515–532.
17. Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington’s disease. Cell. 2000; 101: 57–66.
18. Wheeler VC, Auerbach W, White JK, Srinidhi J, Auerbach A, Ryan A, Duyao MP, Vrbanac V, Weaver M, Gusella JF, Joyner AL, MacDonald ME. Length-dependent gametic CAG repeat instability in the Huntington’s disease knock-in mouse. Hum Mol Genet. 1999; 8: 115–122.
19. Faber PW, Alter JR, MacDonald ME, Hart AC. Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron. Proc Natl Acad Sci U S A. 1999; 96: 179–84.
20. Marsh JL, Walker H, Theisen H, Zhu YZ, Fielder T, Purcell J, Thompson LM. Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila. Hum Mol Genet. 2000; 9: 13–25.
21. Lim D, Fedrizzi L, Tartari M, Zuccato C, Cattaneo E, Brini M, Carafoli E. Calcium homeostasis and mitochondrial dysfunction in striatal neurons of Huntington disease. J Biol Chem. 2008; 283: 5780–5789.
22. Romero E, Cha GH, Verstreken P, Ly CV, Hughes RE, Bellen HJ, Botas J. Suppression of neurodegeneration and increased neurotransmission caused by expanded full-length huntingtin accumulating in the cytoplasm. Neuron. 2008; 57: 27–40.
23. Laforet GA, Sapp E, Chase K, McIntyre C, Boyce FM, Campbell M, Cadigan BA, Warzecki L, Tagle DA, Reddy PH, Cepeda C, Calvert CR, Jokel ES, Klapstein GJ, Ariano MA, Levine MS, DiFiglia M, Aronin N. Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington’s disease. J Neurosci. 2001; 21: 9112–9123.
24. Yang SH, Cheng PH, Banta H, Piotrowska-Nitsche K, Yang JJ, Cheng EC, Snyder B, Larkin K, Liu J, Orkin J, Fang ZH, Smith Y, Bachevalier J, Zola SM, Li SH, Li XJ, Chan AW. Towards a transgenic model of Huntington’s disease in a non-human primate. Nature. 2008; 453: 921–924.
25. Harper SQ, Staber PD, He X, Eliason SL, Martins IH, Mao Q, Yang L, Kotin RM, Paulson HL, Davidson BL. RNA interference improves motor and neuropathological abnormalities in a Huntington’s disease mouse model. Proc Natl Acad Sci U S A. 2005; 102: 5820–5805.
26. DiFiglia M, Sena-Esteves M, Chase K, Sapp E, Pfister E, Sass M, Yoder J, Reeves P, Pandey RK, Rajeev KG, Manoharan M, Sah DW, Zamore PD, Aronin N. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci U S A. 2007; 104: 17204–17209.
27. Van Bilsen PH, Jaspers L, Lombardi MS, Odekerken JC, Burright EN, Kaemmerer WF. Identification and allele-specific silencing of the mutant huntingtin allele in Huntington’s disease patient-derived fibroblasts. Hum Gene Ther. 2008; 19: 710–719.
28. Zhang Y, Engelman J, Friedlander RM. Allele-specific silencing of mutant Huntington’s disease gene. J Neurochem. 2009; 108: 82–90.
29. Boudreau RL, McBride JL, Martins I, Shen S, Xing Y, Carter BJ, Davidson BL Nonallele-specific Silencing of Mutant and Wild-type Huntingtin Demonstrates Therapeutic Efficacy in Huntington’s Disease Mice. Mol Ther 2009; 17: 1053-63.
30. Chan DC. Mitochondria: dynamic organelles in disease, aging, and development. Cell. 2006; 125: 1241–1252.
31. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science. 2004; 305: 626–629.
32. Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998; 281: 1309–1312.
33. Newmeyer DD, Ferguson MS. Mitochondria: releasing power for life and unleashing the machineries of death. Cell. 2003; 112: 481–490.
34. Beal MF. Aging, energy, and oxidative stress in neurodegenerative diseases. Annals of Neurol. 1995; 38: 357–366.
35. Beal MF, Hyman BT, Koroshetz W. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases?, Trends Neurosci. 1993; 16: 125–131.
36. Bowling AC, Beal MF. Bioenergetic and oxidative stress in neurodegenerative diseases. Life Sciences. 1995; 56: 1151–1171.
37. Davis JN, Hunnicutt EJ Jr., Chisholm JC. A mitochondrial bottleneck hypothesis of Alzheimer’s disease. Mol Med Today. 1995; 1: 240–247.
38. Dykens JA. Mitochondrial free radical production and oxidative pathophysiology: implications for neurodegenerative disease, in: M.F. Beal, N. Howell_Eds.., Mitochondria and Free Radicals in Neurodegenerative Diseases, Wiley-Liss, New York, 1997, 29–55.
39. Parker WD Jr. Sporadic neurologic disease and the electron transport chain: a hypothesis, in Pascuzzi_Ed.., Proceedings of the 1989 scientific meeting of the American Society for Neurological Investigation: new developments in neuromuscular disease, Bloomington: Indiana University Printing Services, 1990_1989. pp. 59–64.
40. Parker WD, Parks JK, Filley CM, Kleinschmidt-DeMasters BK. Electron transport defects in Alzheimer’s disease brain. Neurology. 1994; 44: 1090–1096.
41. Swerdlow RH, Parks JK, Miller SW, Tuttle JB, Trimmer PA, Sheehan JP, Bennett JP Jr, Davis RE, Parker WD Jr. Origin and functional consequences of the complex I defect in Parkinson’s disease. Annals Neurol, 1996; 40: 663–671.
42. Swerdlow RH, Parks JK, Cassarino DS, Maguire DJ, Maguire RS, Bennett JP Jr., Davis RE, Parker WD Jr. Cybrids in Alzheimer’s disease: a cellular model of the disease?, Neurology. 1997; 4: 918–925
43. Mattson MP. Neuronal life-and-death signaling, apoptosis, and neurodegenerative disorders. Antioxid Redox Signal. 2006; 8: 1997–2006.
44. Beal MF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol. 1992; 31: 119–130.
45. Brouillet E, Conde F, Beal MF, Hantraye P. Replicating Huntington's disease phenotype in experimental animals. Prog Neurobiol. 1999; 59: 427–468.
46. Ferrante RJ, Kowall NW, Beal MF, Martin JB, Bird ED, Richardson EP Jr. Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington's disease, J Neuropathol Exp Neurol1987; 46: 12–27.
47. Aylward EH, Sparks BF, Field KM, Yallapragada V, Shpritz BD, Rosenblatt A, Brandt J, Gourley LM, Liang K, Zhou H, Margolis RL, Ross CA. Onset and rate of striatal atrophy in preclinical Huntington disease, Neurology. 2004; 63: 66–72.
48. Kassubek J, Juengling FD, Kioschies T, Henkel K, Karitzky J, Kramer B, Ecker D, Andrich J, Saft C, Kraus P, Aschoff AJ, Ludolph AC, Landwehrmeyer GB. Topography of cerebral atrophy in early Huntington's disease: a voxel based morphometric MRI study. J Neurol Neurosurg. Psychiatry. 2004; 75: 213–220.
49. Ruocco HH, Lopes-Cendes I, Li LM, Santos-Silva M, Cendes F. Striatal and extrastriatal atrophy in Huntington's disease and its relationship with length of the CAG repeat. Braz J Med Biol Res. 2006; 39: 1129–1136.
50. Ferrante RJ, Beal MF, Kowall NW, Richardson EP Jr., Martin JB. Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease. Brain Res. 1987; 411: 162–166.
51. Ferrante RJ, Beal MF, Kowall NW, Richardson EP Jr., Bird ED, Martin JB. Selective sparing of a class of striatal neurons in Huntington's disease. Science. 1985; 230: 561–563.
52. Petersen A, Bjorkqvist M. Hypothalamic-endocrine aspects in Huntington's disease. Eur J NeuroSci. 2006; 24: 961–967.
53. Myers RH, Vonsattel JP, Stevens TJ, Cupples LA, Richardson EP, Martin JB, Bird ED. Clinical and neuropathologic assessment of severity in Huntington's disease. Neurology. 1988; 38: 341–347.
54. Browne SE, Beal MF. Oxidative damage in Huntington's disease pathogenesis. Antioxid Redox Signal. 2006; 8: 2061–2073.
55. Jenkins BG, Koroshetz WJ, Beal MF, Rosen BR. Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology. 1993; 43: 2689–2695.
56. Jenkins BG, Rosas HD, Chen YC, Makabe T, Myers R, MacDonald M, Rosen BR, Beal MF, Koroshetz WJ 1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers, Neurology 1998; 50: 1357–1365.
57. Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF 1997 Energy metabolism defects in Huntington's disease and effects of coenzyme Q10, Ann. Neurol. 41: 160–165.
58. Lodi R, Schapira AH, Manners D, Styles P, Wood NW, Taylor DJ, Warner TT Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann Neurol 2000; 48: 72–76.
59. Browne SE. Mitochondria and Huntington’s disease pathogenesis. Insight from Genetic and Chemical Models. Ann N Y Acad Sci 2008; 1147: 358–382.
60. Browne SE, Beal MF The energetics of Huntington’s disease. Neurochem Res 2004; 29: 531–546.
61. Berent S, Giordani B, Lehtinen S, Markel D, Penney JB, Buchtel HA, Starosta-Rubinstein S, Hichwa R, Young AB Positron emission tomographic scan investigations of Huntington’s disease: cerebral metabolic correlates of cognitive function. Ann Neurol 1988; 23: 541–546.
62. Kuhl DE, Metter EJ, Riege WH, Markham CH Patterns of cerebral glucose utilization in Parkinson’s disease and Huntington’s disease. Ann Neurol 1984; 15: Suppl. S119–125.
63. Kuhl DE, Phelps ME, Markham CH, Metter EJ,Riege WH, Winter J Cerebral metabolism and atrophy in Huntington’s disease determined by 18FDG and computed tomographic scan. Ann Neurol 1982; 12: 425–434.
64. Kuwert T, Lange HW, Langen KJ, Herzog H, Aulich A, Feinendegen LE Cortical and subcortical glucose consumption measured by PET in patients with Huntington’s disease. Brain 1990; 113: 1405–1423.
65. Leenders KL, Frackowiak RS, Quinn N, Marsden CD. Brain energymetabolism and dopaminergic function in Huntington’s disease measured in vivo using positron emission tomography. Mov Disord 1986; 1: 69–77.
66. Martin WR, Clark C, Ammann W, Stoessl AJ, Shtybel W, Hayden MR. Cortical glucose metabolism in Huntington’s disease. Neurology. 1992; 42: 223–229.
67. Young AB, Penney JB, Starosta-Rubinstein S, Markel DS, Berent S, Giordani B, Ehrenkaufer R, Jewett D, Hichwa R. PET scan investigations of Huntington’s disease: cerebral metabolic correlates of neurological features and functional decline. Ann Neurol. 1986; 20: 296–303.
68. Goebel HH, Heipertz R, Scholz W, Iqbal K, Tellez-Nagel I. Juvenile Huntington chorea: clinical, ultrastructural, and biochemical studies. Neurology. 1978; 28: 23–31.
69. Tellez-Nagel I, Johnson AB, Terry RD. Studies on brain biopsies of patients with Huntington’s chorea. J Neuropathol Exp Neurol. 1974; 33: 308–332.
70. Kim J, Moody JP, Edgerly CK, Bordiuk OL, Cormier K, Smith K, Beal MF, Ferrante RJ. Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease Human Molecular Genetics. 2010; 19: 3919-3935.
71. Stahl WL, Swanson PD. Biochemical abnormalities in Huntington’s chorea brains, Neurology. 1974; 24: 813–819.
72. Benchoua A, Trioulier Y, Zala D, Gaillard MC, Lefort N, Dufour N, Saudou F, Elalouf JM, Hirsch E, Hantraye P, Déglon N, Brouillet E. Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. Mol Biol Cell. 2006; 17:1652–1663.
73. Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MM, Bird ED, Beal MF. Oxidative damage and metabolic dysfunction in Huntington’s disease: selective vulnerability of the basal ganglia. Ann Neurol. 1997; 41: 646–653.
74. Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Schapira AH. Mitochondrial defect in Huntington’s disease caudate nucleus. Ann Neurol. 1996; 39: 385–389.
75. Mann VM, Cooper JM, Javoy-Agid F,Agid Y, Jenner P, Schapira AH. Mitochondrial function and parental sex effect in Huntington’s disease [letter]. Lancet. 1990; 336: 749.
76. Guidetti P, Charles V, Chen EY, Reddy PH, Kordower JH, Whetsell WO Jr., Schwarcz R, Tagle DA. Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production. Exp Neurol. 2001; 169: 340–350.
77. Brouillet E, Jacquard C, Bizat N, Blum D. 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington’s disease. J Neurochem. 2005; 95: 1521–1540.
78. Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM, Storey E, Srivastava R, Rosen BR, Hyman BT. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 1993; 13: 4181–4192.
79. Brouillet E, Hantraye P, Ferrante RJ, Dolan R, Leroy-Willig A, Kowall NW, Beal MF. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiformmovements in primates. Proc Natl Acad. Sci U.S.A. 1995; 92: 7105–7109.
80. Ferrante RJ, Kowall NW, Richardson EP Jr. Proliferative and degenerative changes in striatal spiny neurons in Huntington’s disease: a combined study using the section-Golgi method and calbindin D28k immunocytochemistry, J Neurosci. 1991; 11: 3877–3887.
81. Brustovetsky N, Brustovetsky T, Purl KJ, Capano M, Crompton M, Dubinsky JM. Increased susceptibility of striatal mitochondria to calcium-induced permeability transition. J Neurosci. 2003; 23: 4858–4867.
82. Lin CH, Tallaksen-Greene S, Chien WM, Cearley JA, Jackson WS, Crouse AB, Ren S, Li XJ, Albin RL, Detloff PJ. Neurological abnormalities in a knock-in mouse model of Huntington’s disease. Hum Mol Genet. 2001; 10: 137–144.
83. Choo YS, Johnson GV, MacDonald M, Detloff PJ, Lesort M. Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum Mol Genet. 2004; 13: 1407–1420.
84. Oliveira JM, Jekabsons MB, Chen S, Lin A, Rego AC, Goncalves J, Ellerby LM, Nicholls DG. Mitochondrial dysfunction in Huntington’s disease: the bioenergetics of isolated and in situ mitochondria from transgenic mice. J Neurochem. 2007; 101: 241–249.
85. Tabrizi SJ, Workman J, Hart PE, Mangiarini L, Mahal A, Bates G, Cooper JM, Schapira AH. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann Neurol. 2000; 47: 80–86.
86. Gizatullina ZZ, Lindenberg KS, Harjes P, Chen Y, Kosinski CM, Landwehrmeyer BG, Ludolph AC, Striggow F, Zierz S, Gellerich FN. Low stability of Huntington muscle mitochondria against Ca2+ in R6/2 mice. Ann Neurol. 2006; 59: 407–411.
87. Mihm MJ, Amann DM, Schanbacher BL, Altschuld RA, Bauer JA, Hoyt KR. Cardiac dysfunction in the R6/2 mouse model of Huntington’s disease. Neurobiol Dis. 2007; 25: 297–308.
88. Trettel F, Rigamonti D, Hilditch-Maguire P, Wheeler VC, Sharp AH, Persichetti F, Cattaneo E, MacDonald ME. Dominant phenotypes produced by the HD mutation in STHdhQ111 striatal cells. Hum Mol Genet. 2000; 9: 2799–2809.
89. Milakovic T, Johnson GV. Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin. J Biol Chem. 2005; 280: 30773–30782.
90. Damiano M, Galvan L, Deglon N, Brouillet E. Mitochondria in Huntington’s disease. Biochim Biophys Acta. 2010; 1802: 52–61.
91. Quintanilla RA, Johnson GV. Role of mitochondrial dysfunction in the pathogenesis of Huntington’s disease. Brain Res Bull. 2009; 80: 242–247
92. Solans A, Zambrano A, Rodriguez M, Barrientos A. Cytotoxicity of a mutant huntingtin fragment in yeast involves early alterations in mitochondrial OXPHOS complexes II and III. Hum Mol Genet. 2006; 15: 3063–3081
93. Sawa A, Wiegand GW, Cooper J, Margolis RL, Sharp AH, Lawler JF Jr., Greenamyre JT, Snyder SH, Ross CA. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat Med. 1999; 5: 1194–1198.
94. Seong IS, Ivanova E, Lee JM, Choo YS, Fossale E, Anderson M, Gusella JF, Laramie JM, Myers RH, Lesort M, MacDonald ME. HD. CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum Mol Genet. 2005; 14: 2871–2880.
95. Gines S, Seong IS, Fossale E, Ivanova E, Trettel F, Gusella JF, Wheeler VC, Persichetti F, MacDonald ME. Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington’s disease knock-in mice. Hum Mol Genet. 2003; 12: 497–508.
96. Ruan Q, Lesort M, MacDonald ME, Johnson GV. Striatal cells from mutant huntingtin knock-in mice are selectively vulnerable to mitochondrial complex II inhibitor-induced cell death through a non-apoptotic pathway. Hum Mol Genet. 2004; 13: 669–681.
97. Bossy-Wetzel E, Schwarzenbacher R, Lipton SA. Molecular pathways to neurodegeneration. Nat Med 2004; 10: Suppl S2–S9.
98. Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, Greenamyre JT. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci. 2002; 5: 731–736.
99. Milakovic T, Quintanilla RA, Johnson GV. Mutant huntingtin expression induces mitochondrial calcium handling defects in clonal striatal cells: functional consequences. J Biol Chem. 2006; 281: 34785–34795.
100. Gellerich FN, Gizatullina Z, Nguyen HP, Trumbeckaite S, Vielhaber S, Seppet E, Zierz S, Landwehrmeyer B, Riess O, von Horsten S, Striggow F. Impaired regulation of brain mitochondria by extramitochondrial Ca2+ in transgenic Huntington disease rats. J Biol Chem. 2008; 283: 30715–30724
101. Oliveira JM, Chen S, Almeida S, Riley R, Goncalves J, Oliveira CR, Hayden MR, Nicholls DG, Ellerby LM, Rego AC. Mitochondrial-dependent Ca2+ handling in Huntington’s disease striatal cells: effect of histone deacetylase inhibitors. J Neurosci. 2006; 26: 11174–11186.
102. Quintanilla RA, Jin YN, Fuenzalida K, Bronfman M, Johnson GV. Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-gamma PPARgamma in the pathogenesis of Huntington disease. J Biol Chem. 2008; 283: 25628–25637.
103. Tang TS, Tu H, Chan EY, Maximov A, Wang Z, Wellington CL, Hayden MR, Bezprozvanny I. Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-1, 4, 5 triphosphate receptor type 1. Neuron. 2003; 39: 227–239.
104. Tang TS, Slow E, Lupu V, Stavrovskaya IG, Sugimori M, Llinas R, Kristal BS, Hayden MR, Bezprozvanny I. Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington’s disease. Proc Natl Acad Sci U S A. 2005; 102: 2602–2607.
105. Kaltenbach LS, Romero E, Becklin RR, Chettier R, Bell R, Phansalkar A, Strand A, Torcassi C, Savage J, Hurlburt A, et al. Huntingtin interacting proteins are genetic modifiers of neurodegeneration. PLoS Gene 2007; 3:e82.
106. Fan MM, Fernandes HB, Zhang LY, Hayden MR, Raymond LA. Altered NMDA receptor trafficking in a yeast artificial chromosome transgenic mouse model of Huntington’s disease. J Neurosci. 2007; 27: 3768–3779.
107. Sun Y, Savanenin A, Reddy PH, Liu YF. Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. J Biol Chem. 2001; 276: 24713–24718.
108. Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, Brundin P, Hayden MR, Raymond LA. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington’s disease. Neuron. 2002; 33: 849–860.
109. Heng MY, Detloff PJ, Wang PL, Tsien JZ, Albin RL. In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease. J Neurosci. 2009; 29: 3200–3205.
110. Rigby M, Le Bourdelles B, Heavens RP, Kelly S, Smith D, Butler A, Hammans R, Hills R, Xuereb JH, Hill RG, et al. The messenger RNAs for the N-methyl-D-aspartate receptor subunits show region-specific expression of different subunit composition in the human brain. Neuroscience. 1996; 73:429–447.
111. Huang CC, Faber PW, Persichetti F, Mittal V, Vonsattel JP, MacDonald ME, Gusella JF Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins. Somat Cell Mol Genet. 1998; 24: 217–233.
112. Perez MK, Paulson HL, Pendse SJ, Saionz SJ, Bonini NM, Pittman RN. Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation. J Cell Biol. 1998; 143: 1457–1470.
113. Shimohata T, Nakajima T, Yamada M, Uchida C, Onodera O, Naruse S, Kimura T, Koide R, Nozaki K, Sano Y, Ishiguro H, Sakoe K, Ooshima T, Sato A, Ikeuchi T, Oyake M, Sato T, Aoyagi Y, Hozumi I, Nagatsu T, Takiyama Y, Nishizawa M, Goto J, Kanazawa I, Davidson I, Tanese N, Takahashi H, Tsuji S. Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nat Genet. 2000; 26: 29–36.
114. Sayer JA, Manczak M, Akileswaran L, Reddy PH, Coghlan VM. Interaction of the nuclear matrix protein NAKAP with HypA and huntingtin: implications for nuclear toxicity in Huntington’s disease pathogenesis. Neuromolecular Med. 2005; 7: 297–310.
115. Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell. 2006; 127: 59–69.
116. St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jäger S, Handschin C, Zheng K, Lin J, Yang W, Simon DK, Bachoo R, Spiegelman BM. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell. 2006; 127: 397–408.
117. Weydt P, Pineda VV, Torrence AE, Libby RT, Satterfield TF, Lazarowski ER, Gilbert ML, Morton GJ, Bammler TK, Strand AD, Cui L, Beyer RP, Easley CN, Smith AC, Krainc D, Luquet S, Sweet IR, Schwartz MW, La Spada AR. Thermoregulatory and metabolic defects in Huntington’s disease transgenic mice implicate PGC-1alpha in Huntington’s disease neurodegeneration. Cell Metab. 2006; 4: 349–362
118. Liang H, Ward WF. PGC-1alpha: a key regulator of energy metabolism. Adv Physiol Educ. 2006; 30: 145–151
119. Lee JM, Ivanova EV, Seong IS, Cashorali T, Kohane I, Gusella JF, MacDonald ME. Unbiased gene expression analysis implicates the huntingtin polyglutamine tract in extra-mitochondrial energy metabolism. PLoS Genet. 2007; 3:e135.
120. Acevedo-Torres K, Berríos L, Rosario N, Dufault V, Skatchkov S, Eaton MJ, Torres-Ramos CA, Ayala-Torres S. Mitochondrial DNA damage is a hallmark of chemically induced and the R6/2 transgenic model of Huntington’s disease. DNA Repair Amst 2009; 8: 126–136
121. Chen CM, Wu YR, Cheng ML, Liu JL, Lee YM, Lee PW, Soong BW, Chiu DT. Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington’s disease patients. Biochem Biophys Res Commun. 2007; 359: 335–340.
122. Banoei MM, Houshmand M, Panahi MS, Shariati P, Rostami M, Manshadi MD, Majidizadeh T. Huntington’s disease and mitochondrial DNA deletions: event or regular mechanism for mutant huntingtin protein and CAG repeats expansion? Cell Mol Neurobiol. 2007; 27: 867–875.
123. Bae BI, Xu H, Igarashi S, Fujimuro M, Agrawal N, Taya N, Hayward SD, Moran TH, Montell C, Ross CA, Snyder SH, Sawa A. p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron. 2005; 47: 29–41.
124. Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, Zucker B, Smith K, Kowall NW, Ratan RR, Luthi-Carter R, Hersch SM. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci. 2003; 23: 9418–9427.
125. Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, Rosa E, Sathasivam K, Ghazi-Noori S, Mahal A, Lowden PA, Steffan JS, Marsh JL, Thompson LM, Lewis CM, Marks PA, Bates GP. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci U. S. A. 2003; 100: 2041–2046.
126. Ryu H, Rosas HD, Hersch SM, Ferrante RJ. The therapeutic role of creatine in Huntington's disease. Pharmacol Ther. 2005; 108: 193–207.
127. Dedeoglu A, Kubilus JK, Yang L, Ferrante KL, Hersch SM, Beal MF, Ferrante RJ. Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. J Neurochem. 2003; 85: 1359–1367.
128. Ferrante RJ, Andreassen OA, Jenkins BG, Dedeoglu A, Kuemmerle S, Kubilus JK, Kaddurah-Daouk R, Hersch SM, Beal MF. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J Neurosci. 2000; 20: 4389–4397.
129. Hersch SM, Gevorkian S, Marder K, Moskowitz C, Feigin A, Cox M, Como P, Zimmerman C, Lin M, Zhang L, Ulug AM, Beal MF, Matson W, Bogdanov M, Ebbel E, Zaleta A, Kaneko Y, Jenkins B, Hevelone N, Zhang H, Yu H, Schoenfeld D, Ferrante R, Rosas HD. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG. Neurology.2006; 66: 250–252.
130. Sorolla MA, Reverter-Branchat G, Tamarit J, Ferrer I, Ros J, Cabiscol E. Proteomic and oxidative stress analysis in human brain samples of Huntington disease. Free Radic Biol Med. 2008; 45: 667–678.
131. Stack EC, Matson WR, Ferrante RJ. Evidence of oxidant damage in Huntington's disease: translational strategies using antioxidants. Ann N Y Acad Sci. 2008; 1147: 79–92.
132. Beal MF, Ferrante RJ. Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat Rev Neurosci. 2004; 5: 373–384.
133. Rebec GV, Barton SJ, Marseilles AM, Collins K. Ascorbate treatment attenuates the Huntington behavioral phenotype in mice. Neuro Report. 2003; 14: 1263–1265.
134. Klivenyi P, Ferrante RJ, Gardian G, Browne S, Chabrier PE, Beal MF. Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease. J Neurochem. 2003; 86: 267–272.
135. Young AJ, Johnson S, Steffens DC, Doraiswamy PM. Coenzyme Q10: a review of its promise as a neuroprotectant. CNS Spectr. 2007; 12: 62–68.
136. Ferrante RJ, Andreassen OA, Dedeoglu A, Ferrante KL, Jenkins BG, Hersch SM, Beal MF. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci. 2002; 22: 1592–1599.
137. Smith KM, Matson S, Matson WR, Cormier K, Del Signore SJ, Hagerty SW, Stack EC, Ryu H, Ferrante RJ. Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice, Biochim. Biophys. Acta .2006; 1762: 616–626.
138. Bachurin SO, Shevtsova EP, Kireeva EG, Oxenkrug GF, Sablin SO. Mitochondria as a target for neurotoxins and neuroprotective agents. Ann N Y Acad Sci. 2003; 993: 334–344.
139. Bachurin S, Bukatina E, Lermontova N, Tkachenko S, Afanasiev A, Grigoriev V, Grigorieva I, Ivanov Y, Sabli S, Zefirov N. Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Ann N Y Acad Sci. 2001; 939: 425–435.
140. Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D. Effect of dimebon on cognition, activities of daily living, behaviour, and global functionin patients with mild-to-moderate Alzheimer’s disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008; 372: 207–215.
141. Wu J, Li Q. Bezprozvanny I. Evaluation of Dimebon in cellular model of Huntington’s disease. Mol Neurodegener 2008; 3: 15.
142. Nieminen AL, Petrie TG, Lemasters JJ, Selman WR. Cyclosporin A delays mitochondrial depolarization induced byN-methyl-d-aspartate in cortical neurons: evidence of the mitochondrial permeability transition. Neuroscience. 1996; 75: 993–997.
143. Petersén A, Castilho RF, Hansson O, Wieloch T, Brundin P. Oxidative stress, mitochondrial permeability transition and activation of caspases in calcium ionophore A23187-induced death of cultured striatal neurons. Brain Res. 2000; 857: 20–29.
144. Leventhal L, Sortwell CE, Hanbury R, Collie TJ, Kordower JH, Palfi S. Cyclosporin A protects striatal neurons in vitro and in vivo from 3 nitropropionic acid toxicity. J Comp Neurol. 2000; 425: 471–478.
145. Merlini L, Angelin A, Tiepolo T, Braghetta P, Sabatelli P, Zamparelli A, Ferlini A, Maraldi NM, Bonaldo P, Bernardi P. Cyclosporin A correctsmitochondrial dysfunction and muscle apoptosis in patients with collagen VI myopathies. Proc Natl Acad Sci U.S.A. 2008; 105: 5225–5229.
146. Seaton TA, Cooper JM, Schapira AH. Cyclosporin inhibition of apoptosis finduced by mitochondrial complex I toxins. Brain Res. 1998, 8091: 12–17.
147. Shehadeh J, Fernandes, Zeron Mullins MM, Graham RK, Leavitt BR, Hayden MR, Raymond LA. Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease. Neurobiol Dis. 2006; 21: 392–403.
148. Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, Deng Y, Oh R, Bissada N, Hossain SM, Yang YZ, Li XJ, Simpson EM, Gutekunst CA, Leavitt BR, Hayden MR. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet. 2003; 12: 1555–15567.
149. Shiga Y, Onodera H, Matsuo Y, Kogure K Cyclosporin. A protects against ischemia-reperfusion injury in the brain. Brain Res. 1992; 595: 145–148.
150. Al-Omar MA. The X-linked adrenoleukodystrophy X-ALD and oxidative stress. Journal of herbal pharmacotherapy. 2006; 6: 125-34.
151. Al-Omar MA, Al-Arifi M. Current and new strategies in therapy of neurodegenerative disorders: amyotrophic lateral sclerosis as a mode. Arabic Journal of Pharmaceutical Sciences. 2005; 3: 105-112.
152. Al-Omar MA, Beedham C, Al-Sarra IA. Pathological roles of reactive oxygen species and their defence mechanisms Saudi Pharmaceutical Journal. 2005; 12: 1-18
153. Friberg H, Ferrand-Drake M, Bengtsson F, Halestrap AP, Wieloch T. CyclosporinA, but not FK506, protects mitochondria and neurons against hypoglycemic damage and implicates the mitochondrial permeability transition in cell death, J Neurosci. 1998; 18: 5151–5159.
154. Okonkwo DO, Povlishock JT. An intrathecal bolus of cyclosporin A before injury preserves mitochondrial integrity and attenuates axonal disruption in traumatic brain injury. J Cereb Blood Flow Metab. 1999; 19: 443–451.
155. Wu CL, Hwang CS, Chen SD, Yin JH, Yang DI. Neuroprotective mechanisms of brain-derived neurotrophic factor against 3-nitropropionic acid toxicity: therapeutic implications for Huntington's disease. Ann N Y Acad Sci. 2010; 1201: 8-12.
156. Wu CL, Hwang CS, Yang DI. Protective effects of brain-derived neurotrophic factor against neurotoxicity of 3-nitropropionic acid in rat cortical neurons. Neurotoxicology. 2009; 4: 718-26. .
157. Gerhart-Hines Z, Rodgers JT, Bare O, Lerin C, Kim SH, Mostoslavsky R, Alt FW, Wu Z, Puigserver P. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha. EMBO J. 2007; 26: 1913–1923.
158. Haigis MC, Mostoslavsky R, Haigis KM, Fahie K, Christodoulou DC, Murphy AJ, Valenzuela DM, Yancopoulos GD, Karow M, Blander G, Wolberger C, Prolla TA, Weindruch R, Alt FW, Guarente L. SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell. 2006; 126: 941–954.
159. Parker JA, Arango M, Abderrahmane S, Lambert E, Tourette C, Catoire H, Neri C. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat Genet. 2005; 37: 349–350.
160. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso m, Puigserver P, Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 2006; 127: 1109–1122.
161. Schopfer FJ, Lin Y, Baker PR, Cui T, Garcia-Barrio M, Zhang J, Chen K, Chen YE, Freeman BA. Nitrolinoleic acid: an endogenous peroxisome proliferatoractivated receptor gamma ligand. Proc Natl Acad Sci U.S.A. 2005; 102: 2340–2345.
162. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med. 2002; 53: 409–435.
163. Sundararajan S, Jiang Q, Heneka M, Landreth G. PPARgamma as a therapeutic target in central nervous system diseases. Neurochem Int. 2006; 49: 136–144.
164. Fuenzalida K, Quintanilla RA, Ramos P, Piderit D, Fuentealba AR, Martinez G. Inestrosa NC, Bronfman M. PPAR gammaup-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis. J Biol Chem. 2007; 282: 37006–37015.
165. Hunter RL, Dragicevic N, Seifert K, Choi DY, Liu M, Kim HC, Cass WA, Sullivan PG, Bing G. Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. J Neurochem. 2007; 100: 1375–1386.
166. Schutz B, Reimann J, Dumitrescu-Ozimek L, Kappes-Horn K, Landreth GE, Schurmann B, Zimmer A, Heneka MT. The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci. 2005; 25: 7805–7812.
167. Strum JC, Shehee R, Virley D, Richardson J, Mattie M, Selley P, Ghosh S, Nock C, Saunders A, Roses A. Rosiglitazone induces mitochondrial biogenesis in mouse brain. J Alzheimers Dis. 2007; 11: 45–51.
168. Al-Omar MA, Youssef KM, El-Sherbeny MA, Awadalla, El-Subbagh HI. Synthesis and In Vitro antioxidant activity of some new fused pyridine analogs. Arch Pharm Chem Life Sci. 2005; 338: 175-180.
169. Al-Omar MA, El-Subbagh HI, Beedham C, Smith J. Role of molybdenum hydroxylases in diseases. Saudi Pharmaceutical Journal. 2005; 13: 1-13.
170. Al-Omar MA. Effect of 2-hydroxy-1,4-naphthoquinone, a natural dye of Henna, on aldehyde oxidase activity in guinea pig liver. Journal of Medical Science. 2005; 5: 163-168.
171. Ma B, Culver BP, Baj G, Tongiorgi E, Chao MV, Tanese N. Localization of BDNF mRNA with the Huntington's disease protein in rat brain. Mol Neurodegener. 2010; 5: 22.
172. Chaturvedi RK, Adhihetty P, Shukla S, Hennessy T, Calingasan N, Yang L, Starkov A, Kiaei M, Cannella M, Sassone J, Ciammola A, Squitieri F, Beal MF. Impaired PGC-1alpha function in muscle in Huntington's disease. Hum Mol Genet 2009; 18: 3048-65.
173. Chaturvedi RK, Adhihetty P, Shukla S, Hennessy T, Calingasan N, Yang L, Starkov A, Kiaei M, Cannella M, Sassone J, Ciammola A, Squitieri F, Beal MF. Impaired PGC-1alpha function in muscle in Huntington's disease. Hum Mol Genet 2009; 18: 3048-65.
174. Ho DJ, Calingasan NY, Wille E, Dumont M, Beal MF. Resveratrol protects against peripheral deficits in a mouse model of Huntington's disease. Exp Neurol 2010; 225: 74-84.
2. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED Richardson EP Jr. Neuropathological classification of Huntington’s disease. J Neuropathol Exp Neurol. 1985; 44: 559–577.
3. Folstein SE. Huntington’s disease. Johns Hopkins University Press 1990.
4. Bates GP. History of genetic disease: the molecular genetics of Huntington disease a history. Nat Rev Genet. 2005; 6: 766–773.
5. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006; 443: 787–795.
6. Montoya A, Price BH, Menear M, Lepage M. Brain imaging and cognitive dysfunctions in Huntington’s disease. J Psychiatry Neurosci. 2006; 31: 21–29.
7. Gusella JF, MacDonald ME, Ambrose CM, Duyao MP. Molecular genetics of Huntington’s disease. Arch Neurol. 1983; 50: 1157–1163.
8. Vonsattel JP, M. DiFiglia M. Huntington disease. J Neuropathol Exp Neurol. 1998; 57: 369–384.
9. Kremer B. Clinical neurology of Huntington's disease. In: Bates G, Harper P, Jones L eds. Huntington's Disease. Oxford University Press; Edition 3; 2002: 28-53.
10. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 1996; 87: 493–506.
11. Reddy PH, Williams M, Charles V, Garrett L, Pike-Buchanan L, Whetsell WO, Jr, Miller G, Tagle DA. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat Genet. 1998; 20: 198–202.
12. Jackson GR, Salecker I, Dong X, Yao X, Arnheim N, Faber PW, MacDonald ME, Zipursky SL. Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons. Neuron. 1998; 21: 633–642.
13. Schilling G, Becher MW, Sharp AH, Jinnah HA, Duan K, Kotzuk JA, Slunt HH, Ratovitski T, Cooper JK, Jenkins NA, Copeland NG, Price DL, Ross CA, Borchelt DR. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet. 1999; 8: 397–407.
14. Kim M, Lee HS, LaForet G, McIntyre C, Martin EJ, Chang P, Kim TW, Williams M, Reddy PH, Tagle D, Boyce FM, Won L, Heller A, Aronin N, DiFiglia M. Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition. J Neurosci. 1999; 19: 964–973
15. Hodgson JG, Agopyan N, Gutekunst CA, Leavitt BR, LePiane F, Singaraja R, Smith DJ, Bissada N, McCutcheon K, Nasir J, Jamot L, Li XJ, Stevens ME, Rosemond E, Roder JC, Phillips AG, Rubin EM, Hersch SM, Hayden MR. A YAC mouse model for Huntington’s disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron. 1999; 23: 181–192.
16. Levine MS, Klapstein GJ, Koppel A, Gruen E, Cepeda C, Vargas ME, Jokel ES, Carpenter EM, Zanjani H, Hurst RS, Efstratiadis A, Zeitlin S, Chesselet MF. Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington’s disease. J Neurosci Res. 1999; 58: 515–532.
17. Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington’s disease. Cell. 2000; 101: 57–66.
18. Wheeler VC, Auerbach W, White JK, Srinidhi J, Auerbach A, Ryan A, Duyao MP, Vrbanac V, Weaver M, Gusella JF, Joyner AL, MacDonald ME. Length-dependent gametic CAG repeat instability in the Huntington’s disease knock-in mouse. Hum Mol Genet. 1999; 8: 115–122.
19. Faber PW, Alter JR, MacDonald ME, Hart AC. Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron. Proc Natl Acad Sci U S A. 1999; 96: 179–84.
20. Marsh JL, Walker H, Theisen H, Zhu YZ, Fielder T, Purcell J, Thompson LM. Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila. Hum Mol Genet. 2000; 9: 13–25.
21. Lim D, Fedrizzi L, Tartari M, Zuccato C, Cattaneo E, Brini M, Carafoli E. Calcium homeostasis and mitochondrial dysfunction in striatal neurons of Huntington disease. J Biol Chem. 2008; 283: 5780–5789.
22. Romero E, Cha GH, Verstreken P, Ly CV, Hughes RE, Bellen HJ, Botas J. Suppression of neurodegeneration and increased neurotransmission caused by expanded full-length huntingtin accumulating in the cytoplasm. Neuron. 2008; 57: 27–40.
23. Laforet GA, Sapp E, Chase K, McIntyre C, Boyce FM, Campbell M, Cadigan BA, Warzecki L, Tagle DA, Reddy PH, Cepeda C, Calvert CR, Jokel ES, Klapstein GJ, Ariano MA, Levine MS, DiFiglia M, Aronin N. Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington’s disease. J Neurosci. 2001; 21: 9112–9123.
24. Yang SH, Cheng PH, Banta H, Piotrowska-Nitsche K, Yang JJ, Cheng EC, Snyder B, Larkin K, Liu J, Orkin J, Fang ZH, Smith Y, Bachevalier J, Zola SM, Li SH, Li XJ, Chan AW. Towards a transgenic model of Huntington’s disease in a non-human primate. Nature. 2008; 453: 921–924.
25. Harper SQ, Staber PD, He X, Eliason SL, Martins IH, Mao Q, Yang L, Kotin RM, Paulson HL, Davidson BL. RNA interference improves motor and neuropathological abnormalities in a Huntington’s disease mouse model. Proc Natl Acad Sci U S A. 2005; 102: 5820–5805.
26. DiFiglia M, Sena-Esteves M, Chase K, Sapp E, Pfister E, Sass M, Yoder J, Reeves P, Pandey RK, Rajeev KG, Manoharan M, Sah DW, Zamore PD, Aronin N. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci U S A. 2007; 104: 17204–17209.
27. Van Bilsen PH, Jaspers L, Lombardi MS, Odekerken JC, Burright EN, Kaemmerer WF. Identification and allele-specific silencing of the mutant huntingtin allele in Huntington’s disease patient-derived fibroblasts. Hum Gene Ther. 2008; 19: 710–719.
28. Zhang Y, Engelman J, Friedlander RM. Allele-specific silencing of mutant Huntington’s disease gene. J Neurochem. 2009; 108: 82–90.
29. Boudreau RL, McBride JL, Martins I, Shen S, Xing Y, Carter BJ, Davidson BL Nonallele-specific Silencing of Mutant and Wild-type Huntingtin Demonstrates Therapeutic Efficacy in Huntington’s Disease Mice. Mol Ther 2009; 17: 1053-63.
30. Chan DC. Mitochondria: dynamic organelles in disease, aging, and development. Cell. 2006; 125: 1241–1252.
31. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science. 2004; 305: 626–629.
32. Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998; 281: 1309–1312.
33. Newmeyer DD, Ferguson MS. Mitochondria: releasing power for life and unleashing the machineries of death. Cell. 2003; 112: 481–490.
34. Beal MF. Aging, energy, and oxidative stress in neurodegenerative diseases. Annals of Neurol. 1995; 38: 357–366.
35. Beal MF, Hyman BT, Koroshetz W. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases?, Trends Neurosci. 1993; 16: 125–131.
36. Bowling AC, Beal MF. Bioenergetic and oxidative stress in neurodegenerative diseases. Life Sciences. 1995; 56: 1151–1171.
37. Davis JN, Hunnicutt EJ Jr., Chisholm JC. A mitochondrial bottleneck hypothesis of Alzheimer’s disease. Mol Med Today. 1995; 1: 240–247.
38. Dykens JA. Mitochondrial free radical production and oxidative pathophysiology: implications for neurodegenerative disease, in: M.F. Beal, N. Howell_Eds.., Mitochondria and Free Radicals in Neurodegenerative Diseases, Wiley-Liss, New York, 1997, 29–55.
39. Parker WD Jr. Sporadic neurologic disease and the electron transport chain: a hypothesis, in Pascuzzi_Ed.., Proceedings of the 1989 scientific meeting of the American Society for Neurological Investigation: new developments in neuromuscular disease, Bloomington: Indiana University Printing Services, 1990_1989. pp. 59–64.
40. Parker WD, Parks JK, Filley CM, Kleinschmidt-DeMasters BK. Electron transport defects in Alzheimer’s disease brain. Neurology. 1994; 44: 1090–1096.
41. Swerdlow RH, Parks JK, Miller SW, Tuttle JB, Trimmer PA, Sheehan JP, Bennett JP Jr, Davis RE, Parker WD Jr. Origin and functional consequences of the complex I defect in Parkinson’s disease. Annals Neurol, 1996; 40: 663–671.
42. Swerdlow RH, Parks JK, Cassarino DS, Maguire DJ, Maguire RS, Bennett JP Jr., Davis RE, Parker WD Jr. Cybrids in Alzheimer’s disease: a cellular model of the disease?, Neurology. 1997; 4: 918–925
43. Mattson MP. Neuronal life-and-death signaling, apoptosis, and neurodegenerative disorders. Antioxid Redox Signal. 2006; 8: 1997–2006.
44. Beal MF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol. 1992; 31: 119–130.
45. Brouillet E, Conde F, Beal MF, Hantraye P. Replicating Huntington's disease phenotype in experimental animals. Prog Neurobiol. 1999; 59: 427–468.
46. Ferrante RJ, Kowall NW, Beal MF, Martin JB, Bird ED, Richardson EP Jr. Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington's disease, J Neuropathol Exp Neurol1987; 46: 12–27.
47. Aylward EH, Sparks BF, Field KM, Yallapragada V, Shpritz BD, Rosenblatt A, Brandt J, Gourley LM, Liang K, Zhou H, Margolis RL, Ross CA. Onset and rate of striatal atrophy in preclinical Huntington disease, Neurology. 2004; 63: 66–72.
48. Kassubek J, Juengling FD, Kioschies T, Henkel K, Karitzky J, Kramer B, Ecker D, Andrich J, Saft C, Kraus P, Aschoff AJ, Ludolph AC, Landwehrmeyer GB. Topography of cerebral atrophy in early Huntington's disease: a voxel based morphometric MRI study. J Neurol Neurosurg. Psychiatry. 2004; 75: 213–220.
49. Ruocco HH, Lopes-Cendes I, Li LM, Santos-Silva M, Cendes F. Striatal and extrastriatal atrophy in Huntington's disease and its relationship with length of the CAG repeat. Braz J Med Biol Res. 2006; 39: 1129–1136.
50. Ferrante RJ, Beal MF, Kowall NW, Richardson EP Jr., Martin JB. Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease. Brain Res. 1987; 411: 162–166.
51. Ferrante RJ, Beal MF, Kowall NW, Richardson EP Jr., Bird ED, Martin JB. Selective sparing of a class of striatal neurons in Huntington's disease. Science. 1985; 230: 561–563.
52. Petersen A, Bjorkqvist M. Hypothalamic-endocrine aspects in Huntington's disease. Eur J NeuroSci. 2006; 24: 961–967.
53. Myers RH, Vonsattel JP, Stevens TJ, Cupples LA, Richardson EP, Martin JB, Bird ED. Clinical and neuropathologic assessment of severity in Huntington's disease. Neurology. 1988; 38: 341–347.
54. Browne SE, Beal MF. Oxidative damage in Huntington's disease pathogenesis. Antioxid Redox Signal. 2006; 8: 2061–2073.
55. Jenkins BG, Koroshetz WJ, Beal MF, Rosen BR. Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology. 1993; 43: 2689–2695.
56. Jenkins BG, Rosas HD, Chen YC, Makabe T, Myers R, MacDonald M, Rosen BR, Beal MF, Koroshetz WJ 1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers, Neurology 1998; 50: 1357–1365.
57. Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF 1997 Energy metabolism defects in Huntington's disease and effects of coenzyme Q10, Ann. Neurol. 41: 160–165.
58. Lodi R, Schapira AH, Manners D, Styles P, Wood NW, Taylor DJ, Warner TT Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann Neurol 2000; 48: 72–76.
59. Browne SE. Mitochondria and Huntington’s disease pathogenesis. Insight from Genetic and Chemical Models. Ann N Y Acad Sci 2008; 1147: 358–382.
60. Browne SE, Beal MF The energetics of Huntington’s disease. Neurochem Res 2004; 29: 531–546.
61. Berent S, Giordani B, Lehtinen S, Markel D, Penney JB, Buchtel HA, Starosta-Rubinstein S, Hichwa R, Young AB Positron emission tomographic scan investigations of Huntington’s disease: cerebral metabolic correlates of cognitive function. Ann Neurol 1988; 23: 541–546.
62. Kuhl DE, Metter EJ, Riege WH, Markham CH Patterns of cerebral glucose utilization in Parkinson’s disease and Huntington’s disease. Ann Neurol 1984; 15: Suppl. S119–125.
63. Kuhl DE, Phelps ME, Markham CH, Metter EJ,Riege WH, Winter J Cerebral metabolism and atrophy in Huntington’s disease determined by 18FDG and computed tomographic scan. Ann Neurol 1982; 12: 425–434.
64. Kuwert T, Lange HW, Langen KJ, Herzog H, Aulich A, Feinendegen LE Cortical and subcortical glucose consumption measured by PET in patients with Huntington’s disease. Brain 1990; 113: 1405–1423.
65. Leenders KL, Frackowiak RS, Quinn N, Marsden CD. Brain energymetabolism and dopaminergic function in Huntington’s disease measured in vivo using positron emission tomography. Mov Disord 1986; 1: 69–77.
66. Martin WR, Clark C, Ammann W, Stoessl AJ, Shtybel W, Hayden MR. Cortical glucose metabolism in Huntington’s disease. Neurology. 1992; 42: 223–229.
67. Young AB, Penney JB, Starosta-Rubinstein S, Markel DS, Berent S, Giordani B, Ehrenkaufer R, Jewett D, Hichwa R. PET scan investigations of Huntington’s disease: cerebral metabolic correlates of neurological features and functional decline. Ann Neurol. 1986; 20: 296–303.
68. Goebel HH, Heipertz R, Scholz W, Iqbal K, Tellez-Nagel I. Juvenile Huntington chorea: clinical, ultrastructural, and biochemical studies. Neurology. 1978; 28: 23–31.
69. Tellez-Nagel I, Johnson AB, Terry RD. Studies on brain biopsies of patients with Huntington’s chorea. J Neuropathol Exp Neurol. 1974; 33: 308–332.
70. Kim J, Moody JP, Edgerly CK, Bordiuk OL, Cormier K, Smith K, Beal MF, Ferrante RJ. Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease Human Molecular Genetics. 2010; 19: 3919-3935.
71. Stahl WL, Swanson PD. Biochemical abnormalities in Huntington’s chorea brains, Neurology. 1974; 24: 813–819.
72. Benchoua A, Trioulier Y, Zala D, Gaillard MC, Lefort N, Dufour N, Saudou F, Elalouf JM, Hirsch E, Hantraye P, Déglon N, Brouillet E. Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. Mol Biol Cell. 2006; 17:1652–1663.
73. Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MM, Bird ED, Beal MF. Oxidative damage and metabolic dysfunction in Huntington’s disease: selective vulnerability of the basal ganglia. Ann Neurol. 1997; 41: 646–653.
74. Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Schapira AH. Mitochondrial defect in Huntington’s disease caudate nucleus. Ann Neurol. 1996; 39: 385–389.
75. Mann VM, Cooper JM, Javoy-Agid F,Agid Y, Jenner P, Schapira AH. Mitochondrial function and parental sex effect in Huntington’s disease [letter]. Lancet. 1990; 336: 749.
76. Guidetti P, Charles V, Chen EY, Reddy PH, Kordower JH, Whetsell WO Jr., Schwarcz R, Tagle DA. Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production. Exp Neurol. 2001; 169: 340–350.
77. Brouillet E, Jacquard C, Bizat N, Blum D. 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington’s disease. J Neurochem. 2005; 95: 1521–1540.
78. Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM, Storey E, Srivastava R, Rosen BR, Hyman BT. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 1993; 13: 4181–4192.
79. Brouillet E, Hantraye P, Ferrante RJ, Dolan R, Leroy-Willig A, Kowall NW, Beal MF. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiformmovements in primates. Proc Natl Acad. Sci U.S.A. 1995; 92: 7105–7109.
80. Ferrante RJ, Kowall NW, Richardson EP Jr. Proliferative and degenerative changes in striatal spiny neurons in Huntington’s disease: a combined study using the section-Golgi method and calbindin D28k immunocytochemistry, J Neurosci. 1991; 11: 3877–3887.
81. Brustovetsky N, Brustovetsky T, Purl KJ, Capano M, Crompton M, Dubinsky JM. Increased susceptibility of striatal mitochondria to calcium-induced permeability transition. J Neurosci. 2003; 23: 4858–4867.
82. Lin CH, Tallaksen-Greene S, Chien WM, Cearley JA, Jackson WS, Crouse AB, Ren S, Li XJ, Albin RL, Detloff PJ. Neurological abnormalities in a knock-in mouse model of Huntington’s disease. Hum Mol Genet. 2001; 10: 137–144.
83. Choo YS, Johnson GV, MacDonald M, Detloff PJ, Lesort M. Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum Mol Genet. 2004; 13: 1407–1420.
84. Oliveira JM, Jekabsons MB, Chen S, Lin A, Rego AC, Goncalves J, Ellerby LM, Nicholls DG. Mitochondrial dysfunction in Huntington’s disease: the bioenergetics of isolated and in situ mitochondria from transgenic mice. J Neurochem. 2007; 101: 241–249.
85. Tabrizi SJ, Workman J, Hart PE, Mangiarini L, Mahal A, Bates G, Cooper JM, Schapira AH. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann Neurol. 2000; 47: 80–86.
86. Gizatullina ZZ, Lindenberg KS, Harjes P, Chen Y, Kosinski CM, Landwehrmeyer BG, Ludolph AC, Striggow F, Zierz S, Gellerich FN. Low stability of Huntington muscle mitochondria against Ca2+ in R6/2 mice. Ann Neurol. 2006; 59: 407–411.
87. Mihm MJ, Amann DM, Schanbacher BL, Altschuld RA, Bauer JA, Hoyt KR. Cardiac dysfunction in the R6/2 mouse model of Huntington’s disease. Neurobiol Dis. 2007; 25: 297–308.
88. Trettel F, Rigamonti D, Hilditch-Maguire P, Wheeler VC, Sharp AH, Persichetti F, Cattaneo E, MacDonald ME. Dominant phenotypes produced by the HD mutation in STHdhQ111 striatal cells. Hum Mol Genet. 2000; 9: 2799–2809.
89. Milakovic T, Johnson GV. Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin. J Biol Chem. 2005; 280: 30773–30782.
90. Damiano M, Galvan L, Deglon N, Brouillet E. Mitochondria in Huntington’s disease. Biochim Biophys Acta. 2010; 1802: 52–61.
91. Quintanilla RA, Johnson GV. Role of mitochondrial dysfunction in the pathogenesis of Huntington’s disease. Brain Res Bull. 2009; 80: 242–247
92. Solans A, Zambrano A, Rodriguez M, Barrientos A. Cytotoxicity of a mutant huntingtin fragment in yeast involves early alterations in mitochondrial OXPHOS complexes II and III. Hum Mol Genet. 2006; 15: 3063–3081
93. Sawa A, Wiegand GW, Cooper J, Margolis RL, Sharp AH, Lawler JF Jr., Greenamyre JT, Snyder SH, Ross CA. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat Med. 1999; 5: 1194–1198.
94. Seong IS, Ivanova E, Lee JM, Choo YS, Fossale E, Anderson M, Gusella JF, Laramie JM, Myers RH, Lesort M, MacDonald ME. HD. CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum Mol Genet. 2005; 14: 2871–2880.
95. Gines S, Seong IS, Fossale E, Ivanova E, Trettel F, Gusella JF, Wheeler VC, Persichetti F, MacDonald ME. Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington’s disease knock-in mice. Hum Mol Genet. 2003; 12: 497–508.
96. Ruan Q, Lesort M, MacDonald ME, Johnson GV. Striatal cells from mutant huntingtin knock-in mice are selectively vulnerable to mitochondrial complex II inhibitor-induced cell death through a non-apoptotic pathway. Hum Mol Genet. 2004; 13: 669–681.
97. Bossy-Wetzel E, Schwarzenbacher R, Lipton SA. Molecular pathways to neurodegeneration. Nat Med 2004; 10: Suppl S2–S9.
98. Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, Greenamyre JT. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci. 2002; 5: 731–736.
99. Milakovic T, Quintanilla RA, Johnson GV. Mutant huntingtin expression induces mitochondrial calcium handling defects in clonal striatal cells: functional consequences. J Biol Chem. 2006; 281: 34785–34795.
100. Gellerich FN, Gizatullina Z, Nguyen HP, Trumbeckaite S, Vielhaber S, Seppet E, Zierz S, Landwehrmeyer B, Riess O, von Horsten S, Striggow F. Impaired regulation of brain mitochondria by extramitochondrial Ca2+ in transgenic Huntington disease rats. J Biol Chem. 2008; 283: 30715–30724
101. Oliveira JM, Chen S, Almeida S, Riley R, Goncalves J, Oliveira CR, Hayden MR, Nicholls DG, Ellerby LM, Rego AC. Mitochondrial-dependent Ca2+ handling in Huntington’s disease striatal cells: effect of histone deacetylase inhibitors. J Neurosci. 2006; 26: 11174–11186.
102. Quintanilla RA, Jin YN, Fuenzalida K, Bronfman M, Johnson GV. Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-gamma PPARgamma in the pathogenesis of Huntington disease. J Biol Chem. 2008; 283: 25628–25637.
103. Tang TS, Tu H, Chan EY, Maximov A, Wang Z, Wellington CL, Hayden MR, Bezprozvanny I. Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-1, 4, 5 triphosphate receptor type 1. Neuron. 2003; 39: 227–239.
104. Tang TS, Slow E, Lupu V, Stavrovskaya IG, Sugimori M, Llinas R, Kristal BS, Hayden MR, Bezprozvanny I. Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington’s disease. Proc Natl Acad Sci U S A. 2005; 102: 2602–2607.
105. Kaltenbach LS, Romero E, Becklin RR, Chettier R, Bell R, Phansalkar A, Strand A, Torcassi C, Savage J, Hurlburt A, et al. Huntingtin interacting proteins are genetic modifiers of neurodegeneration. PLoS Gene 2007; 3:e82.
106. Fan MM, Fernandes HB, Zhang LY, Hayden MR, Raymond LA. Altered NMDA receptor trafficking in a yeast artificial chromosome transgenic mouse model of Huntington’s disease. J Neurosci. 2007; 27: 3768–3779.
107. Sun Y, Savanenin A, Reddy PH, Liu YF. Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. J Biol Chem. 2001; 276: 24713–24718.
108. Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, Brundin P, Hayden MR, Raymond LA. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington’s disease. Neuron. 2002; 33: 849–860.
109. Heng MY, Detloff PJ, Wang PL, Tsien JZ, Albin RL. In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease. J Neurosci. 2009; 29: 3200–3205.
110. Rigby M, Le Bourdelles B, Heavens RP, Kelly S, Smith D, Butler A, Hammans R, Hills R, Xuereb JH, Hill RG, et al. The messenger RNAs for the N-methyl-D-aspartate receptor subunits show region-specific expression of different subunit composition in the human brain. Neuroscience. 1996; 73:429–447.
111. Huang CC, Faber PW, Persichetti F, Mittal V, Vonsattel JP, MacDonald ME, Gusella JF Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins. Somat Cell Mol Genet. 1998; 24: 217–233.
112. Perez MK, Paulson HL, Pendse SJ, Saionz SJ, Bonini NM, Pittman RN. Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation. J Cell Biol. 1998; 143: 1457–1470.
113. Shimohata T, Nakajima T, Yamada M, Uchida C, Onodera O, Naruse S, Kimura T, Koide R, Nozaki K, Sano Y, Ishiguro H, Sakoe K, Ooshima T, Sato A, Ikeuchi T, Oyake M, Sato T, Aoyagi Y, Hozumi I, Nagatsu T, Takiyama Y, Nishizawa M, Goto J, Kanazawa I, Davidson I, Tanese N, Takahashi H, Tsuji S. Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nat Genet. 2000; 26: 29–36.
114. Sayer JA, Manczak M, Akileswaran L, Reddy PH, Coghlan VM. Interaction of the nuclear matrix protein NAKAP with HypA and huntingtin: implications for nuclear toxicity in Huntington’s disease pathogenesis. Neuromolecular Med. 2005; 7: 297–310.
115. Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell. 2006; 127: 59–69.
116. St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jäger S, Handschin C, Zheng K, Lin J, Yang W, Simon DK, Bachoo R, Spiegelman BM. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell. 2006; 127: 397–408.
117. Weydt P, Pineda VV, Torrence AE, Libby RT, Satterfield TF, Lazarowski ER, Gilbert ML, Morton GJ, Bammler TK, Strand AD, Cui L, Beyer RP, Easley CN, Smith AC, Krainc D, Luquet S, Sweet IR, Schwartz MW, La Spada AR. Thermoregulatory and metabolic defects in Huntington’s disease transgenic mice implicate PGC-1alpha in Huntington’s disease neurodegeneration. Cell Metab. 2006; 4: 349–362
118. Liang H, Ward WF. PGC-1alpha: a key regulator of energy metabolism. Adv Physiol Educ. 2006; 30: 145–151
119. Lee JM, Ivanova EV, Seong IS, Cashorali T, Kohane I, Gusella JF, MacDonald ME. Unbiased gene expression analysis implicates the huntingtin polyglutamine tract in extra-mitochondrial energy metabolism. PLoS Genet. 2007; 3:e135.
120. Acevedo-Torres K, Berríos L, Rosario N, Dufault V, Skatchkov S, Eaton MJ, Torres-Ramos CA, Ayala-Torres S. Mitochondrial DNA damage is a hallmark of chemically induced and the R6/2 transgenic model of Huntington’s disease. DNA Repair Amst 2009; 8: 126–136
121. Chen CM, Wu YR, Cheng ML, Liu JL, Lee YM, Lee PW, Soong BW, Chiu DT. Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington’s disease patients. Biochem Biophys Res Commun. 2007; 359: 335–340.
122. Banoei MM, Houshmand M, Panahi MS, Shariati P, Rostami M, Manshadi MD, Majidizadeh T. Huntington’s disease and mitochondrial DNA deletions: event or regular mechanism for mutant huntingtin protein and CAG repeats expansion? Cell Mol Neurobiol. 2007; 27: 867–875.
123. Bae BI, Xu H, Igarashi S, Fujimuro M, Agrawal N, Taya N, Hayward SD, Moran TH, Montell C, Ross CA, Snyder SH, Sawa A. p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron. 2005; 47: 29–41.
124. Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, Zucker B, Smith K, Kowall NW, Ratan RR, Luthi-Carter R, Hersch SM. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci. 2003; 23: 9418–9427.
125. Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, Rosa E, Sathasivam K, Ghazi-Noori S, Mahal A, Lowden PA, Steffan JS, Marsh JL, Thompson LM, Lewis CM, Marks PA, Bates GP. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci U. S. A. 2003; 100: 2041–2046.
126. Ryu H, Rosas HD, Hersch SM, Ferrante RJ. The therapeutic role of creatine in Huntington's disease. Pharmacol Ther. 2005; 108: 193–207.
127. Dedeoglu A, Kubilus JK, Yang L, Ferrante KL, Hersch SM, Beal MF, Ferrante RJ. Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. J Neurochem. 2003; 85: 1359–1367.
128. Ferrante RJ, Andreassen OA, Jenkins BG, Dedeoglu A, Kuemmerle S, Kubilus JK, Kaddurah-Daouk R, Hersch SM, Beal MF. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J Neurosci. 2000; 20: 4389–4397.
129. Hersch SM, Gevorkian S, Marder K, Moskowitz C, Feigin A, Cox M, Como P, Zimmerman C, Lin M, Zhang L, Ulug AM, Beal MF, Matson W, Bogdanov M, Ebbel E, Zaleta A, Kaneko Y, Jenkins B, Hevelone N, Zhang H, Yu H, Schoenfeld D, Ferrante R, Rosas HD. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG. Neurology.2006; 66: 250–252.
130. Sorolla MA, Reverter-Branchat G, Tamarit J, Ferrer I, Ros J, Cabiscol E. Proteomic and oxidative stress analysis in human brain samples of Huntington disease. Free Radic Biol Med. 2008; 45: 667–678.
131. Stack EC, Matson WR, Ferrante RJ. Evidence of oxidant damage in Huntington's disease: translational strategies using antioxidants. Ann N Y Acad Sci. 2008; 1147: 79–92.
132. Beal MF, Ferrante RJ. Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat Rev Neurosci. 2004; 5: 373–384.
133. Rebec GV, Barton SJ, Marseilles AM, Collins K. Ascorbate treatment attenuates the Huntington behavioral phenotype in mice. Neuro Report. 2003; 14: 1263–1265.
134. Klivenyi P, Ferrante RJ, Gardian G, Browne S, Chabrier PE, Beal MF. Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease. J Neurochem. 2003; 86: 267–272.
135. Young AJ, Johnson S, Steffens DC, Doraiswamy PM. Coenzyme Q10: a review of its promise as a neuroprotectant. CNS Spectr. 2007; 12: 62–68.
136. Ferrante RJ, Andreassen OA, Dedeoglu A, Ferrante KL, Jenkins BG, Hersch SM, Beal MF. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci. 2002; 22: 1592–1599.
137. Smith KM, Matson S, Matson WR, Cormier K, Del Signore SJ, Hagerty SW, Stack EC, Ryu H, Ferrante RJ. Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice, Biochim. Biophys. Acta .2006; 1762: 616–626.
138. Bachurin SO, Shevtsova EP, Kireeva EG, Oxenkrug GF, Sablin SO. Mitochondria as a target for neurotoxins and neuroprotective agents. Ann N Y Acad Sci. 2003; 993: 334–344.
139. Bachurin S, Bukatina E, Lermontova N, Tkachenko S, Afanasiev A, Grigoriev V, Grigorieva I, Ivanov Y, Sabli S, Zefirov N. Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Ann N Y Acad Sci. 2001; 939: 425–435.
140. Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D. Effect of dimebon on cognition, activities of daily living, behaviour, and global functionin patients with mild-to-moderate Alzheimer’s disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008; 372: 207–215.
141. Wu J, Li Q. Bezprozvanny I. Evaluation of Dimebon in cellular model of Huntington’s disease. Mol Neurodegener 2008; 3: 15.
142. Nieminen AL, Petrie TG, Lemasters JJ, Selman WR. Cyclosporin A delays mitochondrial depolarization induced byN-methyl-d-aspartate in cortical neurons: evidence of the mitochondrial permeability transition. Neuroscience. 1996; 75: 993–997.
143. Petersén A, Castilho RF, Hansson O, Wieloch T, Brundin P. Oxidative stress, mitochondrial permeability transition and activation of caspases in calcium ionophore A23187-induced death of cultured striatal neurons. Brain Res. 2000; 857: 20–29.
144. Leventhal L, Sortwell CE, Hanbury R, Collie TJ, Kordower JH, Palfi S. Cyclosporin A protects striatal neurons in vitro and in vivo from 3 nitropropionic acid toxicity. J Comp Neurol. 2000; 425: 471–478.
145. Merlini L, Angelin A, Tiepolo T, Braghetta P, Sabatelli P, Zamparelli A, Ferlini A, Maraldi NM, Bonaldo P, Bernardi P. Cyclosporin A correctsmitochondrial dysfunction and muscle apoptosis in patients with collagen VI myopathies. Proc Natl Acad Sci U.S.A. 2008; 105: 5225–5229.
146. Seaton TA, Cooper JM, Schapira AH. Cyclosporin inhibition of apoptosis finduced by mitochondrial complex I toxins. Brain Res. 1998, 8091: 12–17.
147. Shehadeh J, Fernandes, Zeron Mullins MM, Graham RK, Leavitt BR, Hayden MR, Raymond LA. Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease. Neurobiol Dis. 2006; 21: 392–403.
148. Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, Deng Y, Oh R, Bissada N, Hossain SM, Yang YZ, Li XJ, Simpson EM, Gutekunst CA, Leavitt BR, Hayden MR. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet. 2003; 12: 1555–15567.
149. Shiga Y, Onodera H, Matsuo Y, Kogure K Cyclosporin. A protects against ischemia-reperfusion injury in the brain. Brain Res. 1992; 595: 145–148.
150. Al-Omar MA. The X-linked adrenoleukodystrophy X-ALD and oxidative stress. Journal of herbal pharmacotherapy. 2006; 6: 125-34.
151. Al-Omar MA, Al-Arifi M. Current and new strategies in therapy of neurodegenerative disorders: amyotrophic lateral sclerosis as a mode. Arabic Journal of Pharmaceutical Sciences. 2005; 3: 105-112.
152. Al-Omar MA, Beedham C, Al-Sarra IA. Pathological roles of reactive oxygen species and their defence mechanisms Saudi Pharmaceutical Journal. 2005; 12: 1-18
153. Friberg H, Ferrand-Drake M, Bengtsson F, Halestrap AP, Wieloch T. CyclosporinA, but not FK506, protects mitochondria and neurons against hypoglycemic damage and implicates the mitochondrial permeability transition in cell death, J Neurosci. 1998; 18: 5151–5159.
154. Okonkwo DO, Povlishock JT. An intrathecal bolus of cyclosporin A before injury preserves mitochondrial integrity and attenuates axonal disruption in traumatic brain injury. J Cereb Blood Flow Metab. 1999; 19: 443–451.
155. Wu CL, Hwang CS, Chen SD, Yin JH, Yang DI. Neuroprotective mechanisms of brain-derived neurotrophic factor against 3-nitropropionic acid toxicity: therapeutic implications for Huntington's disease. Ann N Y Acad Sci. 2010; 1201: 8-12.
156. Wu CL, Hwang CS, Yang DI. Protective effects of brain-derived neurotrophic factor against neurotoxicity of 3-nitropropionic acid in rat cortical neurons. Neurotoxicology. 2009; 4: 718-26. .
157. Gerhart-Hines Z, Rodgers JT, Bare O, Lerin C, Kim SH, Mostoslavsky R, Alt FW, Wu Z, Puigserver P. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha. EMBO J. 2007; 26: 1913–1923.
158. Haigis MC, Mostoslavsky R, Haigis KM, Fahie K, Christodoulou DC, Murphy AJ, Valenzuela DM, Yancopoulos GD, Karow M, Blander G, Wolberger C, Prolla TA, Weindruch R, Alt FW, Guarente L. SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell. 2006; 126: 941–954.
159. Parker JA, Arango M, Abderrahmane S, Lambert E, Tourette C, Catoire H, Neri C. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat Genet. 2005; 37: 349–350.
160. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso m, Puigserver P, Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 2006; 127: 1109–1122.
161. Schopfer FJ, Lin Y, Baker PR, Cui T, Garcia-Barrio M, Zhang J, Chen K, Chen YE, Freeman BA. Nitrolinoleic acid: an endogenous peroxisome proliferatoractivated receptor gamma ligand. Proc Natl Acad Sci U.S.A. 2005; 102: 2340–2345.
162. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med. 2002; 53: 409–435.
163. Sundararajan S, Jiang Q, Heneka M, Landreth G. PPARgamma as a therapeutic target in central nervous system diseases. Neurochem Int. 2006; 49: 136–144.
164. Fuenzalida K, Quintanilla RA, Ramos P, Piderit D, Fuentealba AR, Martinez G. Inestrosa NC, Bronfman M. PPAR gammaup-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis. J Biol Chem. 2007; 282: 37006–37015.
165. Hunter RL, Dragicevic N, Seifert K, Choi DY, Liu M, Kim HC, Cass WA, Sullivan PG, Bing G. Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. J Neurochem. 2007; 100: 1375–1386.
166. Schutz B, Reimann J, Dumitrescu-Ozimek L, Kappes-Horn K, Landreth GE, Schurmann B, Zimmer A, Heneka MT. The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci. 2005; 25: 7805–7812.
167. Strum JC, Shehee R, Virley D, Richardson J, Mattie M, Selley P, Ghosh S, Nock C, Saunders A, Roses A. Rosiglitazone induces mitochondrial biogenesis in mouse brain. J Alzheimers Dis. 2007; 11: 45–51.
168. Al-Omar MA, Youssef KM, El-Sherbeny MA, Awadalla, El-Subbagh HI. Synthesis and In Vitro antioxidant activity of some new fused pyridine analogs. Arch Pharm Chem Life Sci. 2005; 338: 175-180.
169. Al-Omar MA, El-Subbagh HI, Beedham C, Smith J. Role of molybdenum hydroxylases in diseases. Saudi Pharmaceutical Journal. 2005; 13: 1-13.
170. Al-Omar MA. Effect of 2-hydroxy-1,4-naphthoquinone, a natural dye of Henna, on aldehyde oxidase activity in guinea pig liver. Journal of Medical Science. 2005; 5: 163-168.
171. Ma B, Culver BP, Baj G, Tongiorgi E, Chao MV, Tanese N. Localization of BDNF mRNA with the Huntington's disease protein in rat brain. Mol Neurodegener. 2010; 5: 22.
172. Chaturvedi RK, Adhihetty P, Shukla S, Hennessy T, Calingasan N, Yang L, Starkov A, Kiaei M, Cannella M, Sassone J, Ciammola A, Squitieri F, Beal MF. Impaired PGC-1alpha function in muscle in Huntington's disease. Hum Mol Genet 2009; 18: 3048-65.
173. Chaturvedi RK, Adhihetty P, Shukla S, Hennessy T, Calingasan N, Yang L, Starkov A, Kiaei M, Cannella M, Sassone J, Ciammola A, Squitieri F, Beal MF. Impaired PGC-1alpha function in muscle in Huntington's disease. Hum Mol Genet 2009; 18: 3048-65.
174. Ho DJ, Calingasan NY, Wille E, Dumont M, Beal MF. Resveratrol protects against peripheral deficits in a mouse model of Huntington's disease. Exp Neurol 2010; 225: 74-84.
Published
01-04-2011
Statistics
Abstract Display: 200 
PDF Downloads: 357
Dimension Badge
How to Cite
“HUNTINGTON DISEASE: CURRENT ADVANCES IN PATHOGENESIS AND RECENT THERAPEUTIC STRATEGIES”. International Journal of Pharmaceutical Sciences and Drug Research, vol. 3, no. 2, Apr. 2011, pp. 69-79, https://doi.org/10.25004/IJPSDR.2011.030201.
Issue
Section
Review Article
How to Cite
“HUNTINGTON DISEASE: CURRENT ADVANCES IN PATHOGENESIS AND RECENT THERAPEUTIC STRATEGIES”. International Journal of Pharmaceutical Sciences and Drug Research, vol. 3, no. 2, Apr. 2011, pp. 69-79, https://doi.org/10.25004/IJPSDR.2011.030201.
